Viromed Medical AG (XTER:VME) EBIT: €-0.53 Mil (TTM As of Dec. 2025)


XTER:VME Viromed Medical AG XTER:VME
15 GF Score
Price €7.20
! 5 Warning Signs
View Full Analysis

What is Viromed Medical AG EBIT?

Viromed Medical AG XTER:VME -2.04% 15 EBIT is €-0.53 Mil as of Dec. 2025. GuruFocus rates XTER:VME with a GF Score™ of 15/100. The stock has 5 warning signs investors should review.

Viromed Medical AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-0.27 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.53 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Viromed Medical AG's annualized ROC % for the quarter that ended in Dec. 2025 was -7.01%. Viromed Medical AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -23.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Viromed Medical AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -0.35%.

Viromed Medical AG  (XTER:VME) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Viromed Medical AG's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-1.16 * ( 1 - 0% )/( (21.117 + 11.987)/ 2 )
=-1.16/16.552
=-7.01 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21.384 - 0.899 - ( 0.002 - max(0, 0.899 - 0.267+0.002))
=21.117

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13.914 - 1.563 - ( 0.364 - max(0, 2.072 - 5.682+0.364))
=11.987

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Viromed Medical AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.53/( ( (0 + max(-0.648, 0)) + (1.274 + max(3.153, 0)) )/ 2 )
=-0.53/( ( 0 + 4.427 )/ 2 )
=-0.53/2.2135
=-23.94 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.252 + 0 + -0.001) - (0.899 + 0 + 0)
=-0.648

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.116 + 0.722 + 3.378) - (1.563 + 0 + 0.5)
=3.153

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Viromed Medical AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-0.534/151.582
=-0.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viromed Medical AG EBIT Related Terms

Viromed Medical AG EBIT Historical Data

* Premium members only.

The historical data trend for Viromed Medical AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viromed Medical AG EBIT Chart

Viromed Medical AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-0.01 -0.16 -0.11 -3.39 -0.53

Viromed Medical AG Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only 0.07 -0.16 -3.24 -0.27 -0.27

XTER:VME vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Viromed Medical AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viromed Medical AG EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Viromed Medical AG's EV-to-EBIT falls into.


XTER:VME
15GF Score
Viromed Medical AG XTER:VME
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viromed Medical AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-0.53 Mil mean?
Viromed Medical AG (XTER:VME) has a EBIT of €-0.53 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Viromed Medical AG.
Is Viromed Medical AG's EBIT too high?
Viromed Medical AG's current EBIT is €-0.53 Mil. Overall, Viromed Medical AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's EBIT compare to ABT and SYK?
Viromed Medical AG's EBIT of €-0.53 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Viromed Medical AG. Viromed Medical AG's current EBIT is €-0.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (XTER:VME) has a current EBIT of €-0.53 Mil. The current EBIT is €-0.53 Mil. Viromed Medical AG's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Viromed Medical AG (XTER:VME), the current EBIT is €-0.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viromed Medical AG Business Description

Address Hauptstrasse 105, Rellingen, Pinneberg, SH, DEU, 25462
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
15GF Score

Get the complete analysis for XTER:VME

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.20
Price